OCT-1547 is a new substance which is expected to work against the osteoporosis.
An official from Oscotec Inc. said, "If the application will be approved, we are going to conduct Phase 1 clinical trial through Kendle International."
The Phase 1 clinical trial is to be carried out on healthy menopausal women. And after the oral administration of OCT-1547, its satety, tolerability and efficacy will be tested.
The application is currently under review. <헬스코리아뉴스>
저작권자 © 헬스코리아뉴스 무단전재 및 재배포 금지